Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Spain

Marie Skłodowska-Curie Action · Running

Adaptmet Deconstructing adaptive evolution of metastasis

Coordinator
Fundacio Institut De Recerca Biomedica (irb Barcelona), Spain
Runs
1 March 2025 to 28 February 2029
Status
Running
EU funding
€3.5m
Total cost
—
Partners
22 organisations in 10 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101169223

What the project is doing

In the project's own words, from its summary on CORDIS.

Adaptmet aims to develop an advanced training program encompassing the multifaceted aspects of metastasis adaptation mechanisms, intending to equip budding researchers with the necessary skills to emerge as leaders in this field. A robust mentoring and training strategy, coupled with cutting-edge methodologies and a diverse range of complementary soft skills, are crucial to this endeavour. These skills are imparted through local and network-wide events, fostering seamless research progression, and nurturing successful career trajectories.

Scientifically, Adaptmet addresses an unmet medical need by harnessing basic science to revolutionize drug development and, ultimately, enhance patient care. Specifically, scientific work packages (WPs) have been designed to approach metastasis from various functional perspectives. In order to metastasize, cancer cells must adeptly coordinate diverse cellular functions (Cell Fate - WP1). Additionally, understanding the intricate interactions between metastatic cells, the host immune system, and tissue stroma is pivotal (Environment – WP2).

Crucial aspects such as the kinetics of metastasis and the mechanisms governing latency, particularly, remain inadequately understood (Latency – WP3). Clarifying this complexity, unravelling mechanisms underlying therapy failure, and identifying expansion pathways are central to defining novel therapeutic targets (Expansion – WP4). In essence, Adaptmet stands at the intersection of a rapidly evolving multidisciplinary domain, amalgamating distinct fields that often face challenges in mutual communication.

The success of Adaptmet hinges upon robust partnerships, open exchange of ideas, state-of-the-art methodologies and equipment, and the exploitation of synergistic opportunities among network members. This collaboration spans diverse perspectives, bridging gaps between different disciplines, thereby breaking down barriers and fostering interdisciplinary cohesion.

Topics

Who is involved

OrganisationCityCountryRole
Fundacio Institut De Recerca Biomedica (irb Barcelona)BarcelonaSpainCoordinator
Boehringer Ingelheim Rcv GmbH & Co KgWienAustriaParticipant
Forschungsinstitut Fur Molekulare Pathologie Gesellschaft MbhWienAustriaParticipant
Universitat WienWienAustriaAssociatedpartner
Cancer State TherapeuticsCharleroiBelgiumParticipant
Universite Libre De BruxellesBruxellesBelgiumParticipant
Universitat BaselBaselSwitzerlandAssociatedpartner
Universite De LausanneLausanneSwitzerlandAssociatedpartner
Saso KocevarHeidelbergGermanyAssociatedpartner
Danmarks Tekniske UniversitetKongens LyngbyDenmarkAssociatedpartner
Zs Associates ASKgs LyngbyDenmarkParticipant
Fundacio De Recerca Clinic Barcelona-Institut D Investigacions Biomediques August Pi I SunyerBarcelonaSpainParticipant
Fundacio Institut De Recerca Contra La Leucemia Josep CarrerasBadalonaSpainParticipant
Fundacio Institut Hospital Del Mar D Investigacions MediquesBarcelonaSpainAssociatedpartner
Gr Espanol De Estudio Y Tratamientode Intensific. Y Otras Estrateg.experiment. En Tumores Solidos - Grupo SoltiBarcelonaSpainAssociatedpartner
Scienseed SLMadridSpainAssociatedpartner
Universitat De BarcelonaBarcelonaSpainAssociatedpartner
Helsingin YliopistoHelsinkiFinlandParticipant
Academisch Ziekenhuis LeidenLeidenNetherlandsAssociatedpartner
Stichting Het Nederlands Kanker Instituut-Antoni Van Leeuwenhoek ZiekenhuisAmsterdamNetherlandsParticipant
Lunds UniversitetLundSwedenParticipant
Institute of Cancer Research: the Royal Cancer Hospital LbgLondonUnited KingdomAssociatedpartner

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI